EC Number |
Inhibitors |
Structure |
---|
3.4.21.94 | (2R)-1-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[(1R)-2-cyclohexyl-1-[[(2S)-2-[[(2R)-2-(cyclohexylmethyl)piperazin-1-yl]methyl]pyrrolidin-1-yl]methyl]ethyl]-2-(cyclohexylmethyl)piperazine |
- |
|
3.4.21.94 | (2R)-4-((R)-1-cyclohexyl-3-((S)-2-(((R)-2-(cyclohexylmethyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-2-(cyclohexylmethyl)-1-(2-(4-isobutylphenyl)propyl)piperazine |
- |
|
3.4.21.94 | (2R)-4-((R)-1-cyclohexyl-3-((S)-2-(((S)-2-(cyclohexylmethyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-2-(cyclohexylmethyl)-1-(2-(4-isobutylphenyl)propyl)piperazine |
- |
|
3.4.21.94 | (R)-1-((4-tert-butylcyclohexyl)methyl)-4-((R)-1-cyclohexyl-3-((S)-2-(((S)-2-(cyclohexylmethyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-2-(cyclohexylmethyl)piperazine |
- |
|
3.4.21.94 | 7B2 C-terminal peptide |
- |
|
3.4.21.94 | 7B2 CT peptide |
potent specific inhibition of PC2 |
|
3.4.21.94 | CT peptide |
a PC2-specific inhibitor |
|
3.4.21.94 | cystatin-related epidiymal spermatogenic protein |
competitive inhibitor |
|
3.4.21.94 | decanoyl-Arg-Val-Lys-Arg-chloromethylketone |
- |
|
3.4.21.94 | more |
starvation reduces the serum levels of leptin which decreases PC1 expression, the effect can be reversed by administration of exogenous leptin |
|